Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

Kishan J. Pandya, Anuradha R. Thummala, Jennifer J. Griggs, Joseph D. Rosenblatt, Deepak M. Sahasrabudhe, Thomas J. Guttuso, Gary R. Morrow, Joseph A. Roscoe

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

Original languageEnglish (US)
Pages (from-to)87-89
Number of pages3
JournalBreast cancer research and treatment
Volume83
Issue number1
DOIs
StatePublished - Jan 2004

Keywords

  • Breast cancer
  • Gabapentin
  • Hot flashes
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Pandya, K. J., Thummala, A. R., Griggs, J. J., Rosenblatt, J. D., Sahasrabudhe, D. M., Guttuso, T. J., Morrow, G. R., & Roscoe, J. A. (2004). Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast cancer research and treatment, 83(1), 87-89. https://doi.org/10.1023/B:BREA.0000010676.54597.22